NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
April 19, 2024 08:00 ET
|
NeuroMetrix, Inc.
NeuroMetrix today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders.
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
March 14, 2024 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck...
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
March 13, 2024 09:00 ET
|
NeuroMetrix, Inc.
NeuroMetrix today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in Dec 2022.
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
February 22, 2024 07:00 ET
|
NeuroMetrix, Inc.
NeuroMetrix, Inc. today reported financial and business highlights for the quarter and full year ended December 31, 2023.
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
February 15, 2024 09:00 ET
|
NeuroMetrix, Inc.
NeuroMetrix plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024.
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
February 13, 2024 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), a commercial stage medical device company focused on reducing the impact of neurological disorders and pain...
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024
January 08, 2024 09:43 ET
|
NeuroMetrix, Inc.
NeuroMetrix announced today that the Company’s Chairman and CEO, Dr. Shai N. Gozani will present at the Emerging Growth Conference on January 10, 2024.
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
December 12, 2023 09:00 ET
|
NeuroMetrix, Inc.
NeuroMetrix reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patients with Long COVID.
NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)
December 05, 2023 09:00 ET
|
NeuroMetrix, Inc.
NeuroMetrix noted publication of results from a NIH-funded clinical trial of Quell. The paper has been electronically published in The Journal of Pain.
NeuroMetrix Announces One-for-Eight Reverse Stock Split
November 20, 2023 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that it will effect a one-for-eight reverse split of its common stock, effective at 5:00...